Back to School: How biopharma can reboot drug development. Access exclusive analysis here

OxiGene's Zybrestat meets Phase II endpoint

OxiGene (OXGN; SSE:OXGN) said that Zybrestat combretastatin A4P ( CA4P) met

Read the full 110 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE